Skip to content
Home/Companies/Pharma/XERIS Pharmaceuticals

XERIS Pharmaceuticals

Pharma·US·Exited 2018·Held 1yr
Entry
2017
Hold
1yr
Exit
2018

Who owns XERIS Pharmaceuticals?

XERIS Pharmaceuticals is an American Pharma company, formerly owned by Merieux Equity Partners, exited in 2018 (exit via IPO). No current private equity owner is on file.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Merieux Equity Partners
Investor
Merieux Equity Partners
Mérieux Innovation 1 · 2014 · VC

Key facts

HQUS
SectorPharma
StatusAcquired
Exit Type
IPO
Buyer
Nasdaq listing (XERS)
Exit Year
2018

More from Mérieux Innovation 1

Other portfolio companies in the same fund.

Broken String Biosciences
Broken String Biosciences
Active
BiotechUK· 2023
InnoSyn
InnoSyn
Active
PharmaNetherlands· 2023
LabQuality
LabQuality
Exited 2025
HealthcareFrance· 2023
to Aurevia
Cairdac
Cairdac
Active
MedTechFrance· 2022
Mablink Bioscience
Exited 2023
BiotechFrance· 2022
to Eli Lilly and Company
SeqOne Genomics
SeqOne Genomics
Active
BiotechFrance· 2022

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Advantice Health
Advantice Health
Active
TA AssociatesUS
Alcala Farma
Active
Advent InternationalSpain
Alvogen
Alvogen
Active
CVC Capital Partners
Anovo
Anovo
Active
ArdianUS

Questions

Who owns XERIS Pharmaceuticals?

XERIS Pharmaceuticals was formerly owned by Merieux Equity Partners, exited in 2018. No current private equity owner is on file.

Who did XERIS Pharmaceuticals sell to?

Merieux Equity Partners sold XERIS Pharmaceuticals to Nasdaq listing in 2018 (IPO).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue